Stockscreener 앱 받기
1.99
11.16%
-0.25
Skye Bioscience Inc 주식(SKYE)의 최신 뉴스
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE) - ACCESS Newswire
Skye Bioscience, Inc. (NASDAQ:SKYE) Holdings Increased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Has $1.15 Million Stake in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience to Participate in May Investment and Medical Conferences - GlobeNewswire
Clinical-Stage Biotech Skye Sets Triple Conference Schedule: Key Obesity Drug Updates Coming in May - Stock Titan
Skye Bioscience (SKYE) Grants Stock Options to New Employee | SK - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Skye Bioscience Board Approves 19,000 Share Options Grant Under 2024 Inducement Plan - Stock Titan
Skye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive Plan - Nasdaq
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com
SIMPLY BETTER BRANDS ANNOUNCES RESULTS FOR FISCAL 2024, HIGHLIGHTING 77% INCREASE IN TRUBAR™ REVENUE, AND CORPORATE NAME CHANGE TO TRUBAR INC. - The Globe and Mail
William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat
(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com
SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World
William Blair Predicts Skye Bioscience Q1 Earnings - Defense World
Brokers Offer Predictions for Skye Bioscience Q1 Earnings - Defense World
Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) PT at $16.60 - Defense World
Brokers Issue Forecasts for Skye Bioscience Q2 Earnings - Defense World
Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha
Skye Bioscience reports promising obesity treatment study By Investing.com - Investing.com South Africa
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga
Skye Bioscience (SKYE) Schedules Key Meetings at Biopharma Symposium - GuruFocus
Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga
Skye Bioscience soars after experimental weight-loss drug shows promise in mice - TradingView
Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga
Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - marketscreener.com
Skye Bioscience's (SKYE) Nimacimab Shows Promising Weight Loss R - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model | SKYE Stock News - GuruFocus
Skye Bioscience reports promising obesity treatment study - Investing.com
Skye Bioscience Demonstrates Over 30% Weight Loss with - GlobeNewswire
Skye Bioscience (SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - StreetInsider
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - markets.businessinsider.com
Skye Bioscience to Conduct Meetings at Piper Sandler Conference - GuruFocus
Major Obesity Drug Developer Skye Bio Takes Center Stage at Prestigious Investor Conference - Stock Titan
Skye Bioscience (NASDAQ:SKYE) Shares Down 50.8% – Here’s Why - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Down 50.8% – What’s Next? - Defense World
Skye Bioscience, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsSKYE - ACCESS Newswire
Let's Tokyo! WestJet bolsters connectivity between Calgary and Japan with new daily year-round service - The Globe and Mail
VOO ETF News, 4/4/2025 - The Globe and Mail
Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World
Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
0.39%
3.66%
자본화:
|
볼륨(24시간):